BRIM appearing on BioCentury: How BRIM is bridging a translational science gap in Taiwan2015-11-16
Bridge to POC
BRIM Biotechnology Inc. has assembled a team of translational science veterans to fill what it sees as a gap in Taiwanese drug development capabilities. The company plans to bring in preclinical projects with global commercialization potential and develop them through Phase Ia or IIb proof of concept, then sell them or find a partner to complete development outside of Taiwan or Asia.
BRIM seeks global rights to programs from academic groups, multinationals and biotechs. The company has four preclinical programs, including two cancer biologics and one dengue fever collaboration with a Johnson & Johnson unit.
BRIM Biotechnology Announces Strategic Collaboration with Johnson & Johnson Innovation to Advance New Treatments for Dengue2015-06-11
TAIPEI, June 11, 2015 /PRNewswire/ — BRIM Biotechnology, Inc. (“BRIM”), announced today that it has entered a Collaboration, Option and License Agreement with Janssen Pharmaceutica N.V. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement, which was facilitated by Johnson & Johnson Innovation, the parties will pursue the research, development and commercialization of certain compounds identified by Janssen that are targeted for dengue indications.
全福生技宣布與嬌生公司(Johnson & Johnson)策略合作 開發登革熱新藥2015-06-11
台北訊，2015年6月11日﹣全福生技今天宣布與嬌生公司(Johnson & Johnson)旗下的楊森藥廠(Janssen Pharmaceutica N.V. , Janssen)簽訂一項合作、選擇權與授權合約。該新藥開發案由嬌生公司創新部門（Johnson & Johnson Innovation）主導推動，並由雙方就楊森藥廠已針對登革熱為適應症所開發選定之特定化合物進行研究、開發及商業化。[*Read more ...]
Johnson & Johnson Innovation Announces 17 Collaborations With Focus on Advancing Global Healthcare Through Transformational Science and Technologies2015-06-11
[*Read more ...]